tradingkey.logo
tradingkey.logo
Search

Hims & Hers Health Launches Lab Testing with Quest Diagnostics

TigerFeb 4, 2026 2:21 PM
facebooktwitterlinkedin
View all comments0

Hims & Hers Health Inc. is expanding into lab testing services as part of its growing focus on preventive healthcare, according to Dow Jones.

U.S.-listed shares of the company rose 6% in premarket trading.

The telehealth platform will allow customers to access testing at more than 1,000 Quest Diagnostics locations nationwide. After testing, users will receive results and consult with providers on the Hims & Hers platform to develop personalized health plans that may include prescriptions, supplements, or nutrition guidance.

The company offers two pricing tiers: a $199 annual plan for one blood draw covering 50 biomarker tests, and a $499 plan that includes two blood draws and 120 biomarker tests. These tests evaluate various health aspects including heart health, metabolism, hormones, inflammation, and stress.

Chief Executive Andrew Dudum believes the service will be accessible to most Americans. "It’s a price point that I think the majority of the country can afford," he said.

Dudum expects this preventive care initiative to attract new users beyond the company’s established customer base for hair loss, weight loss, and sexual health treatments. He projects the lab testing service will eventually grow into a $1 billion business.

"You know, size of this market is, I think every single person in the country," Dudum stated regarding the potential reach of the new offering.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.